Prescription RequiredMOUNJARO KwikPen (Tirzepatide) 7.5 mg/0.6 mL is a prescription once-weekly injectable medicine used to improve blood sugar control in adults with type 2 diabetes. It contains tirzepatide, a dual GIP and GLP-1 receptor agonist that helps regulate blood glucose levels, reduce appetite, and support weight management when combined with a healthy diet and regular exercise. The 7.5 mg dose is typically prescribed as a maintenance dose based on individual treatment needs.
| Generic name | Tirzepatide |
| Strength | 7.5 mg |
| Manufacturer | Eli Lilly and Company |
| Package size | 1 pre-filled 2.4 ml pen |
| Used for | Type 2 diabetes and chronic weight management |
| Availability | In Stock |
| Shipping to | USA, UK, Australia, Canada, New Zealand, Philippines, Tunisia, France, Italy, South Korea, Albania, Romania, Hong Kong, Malaysia, Thailand, Singapore, UAE, Georgia, Armenia, Saudi Arabia, Qatar, Kuwait, South Africa, and many other countries. |
Tirzepatide 7.5 mg works by activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It increases insulin release when blood sugar levels are elevated, decreases glucagon production, slows stomach emptying, and helps control appetite. These combined actions improve blood sugar control and support weight management.
